Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Krystal Biotech, Inc. (KRYS) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/07/2023 8-K Quarterly results
Docs: "Krystal Biotech Announces Second Quarter 2023 Financial Results and Operational Highlights"
05/08/2023 8-K Quarterly results
Docs: "Krystal Biotech Announces First Quarter 2023 Financial Results and Operational Highlights"
11/07/2022 8-K Quarterly results
08/08/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
11/08/2021 8-K Quarterly results
Docs: "Krystal Biotech Reports Third Quarter 2021 Financial Results and Provides Update on Operational Progress"
05/10/2021 8-K Quarterly results
11/09/2020 8-K Quarterly results
Docs: "Krystal Biotech Reports Third Quarter 2020 Financial Results and Provides Update on Operational Progress",
"Presentation on KB407 for the treatment of cystic fibrosis",
"Corporate Presentation for November 2020"
08/10/2020 8-K Quarterly results
05/04/2020 8-K Quarterly results
Docs: "Krystal Biotech Reports First Quarter 2020 Financial Results and Provides Update on Operational Progress"
11/04/2019 8-K/A Quarterly results
Docs: "Krystal Biotech Reports Third Quarter 2019 Financial and Operating Results"
08/05/2019 8-K Quarterly results
Docs: "Krystal Biotech Reports Second Quarter 2019 Financial and Operating Results"
05/10/2019 8-K Quarterly results
Docs: "Krystal Biotech Reports First Quarter 2019 Financial Results and Provides Corporate Update"
11/05/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 5, 2018 KRYSTAL BIOTECH, INC. Delaware 001-38210 82-1080209 2100 Wharton Street, Suite 701 Pittsburgh, Pennsylvania 15203 Registrant's telephone number, including area code: 586-5830 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-co...",
"Krystal Biotech Reports Third Quarter 2018 Financial Results and Provides Corporate Update"
05/08/2018 8-K Quarterly results
Docs: "SIGNATURES",
"Krystal Biotech Reports First Quarter 2018 Financial Results and Provides Corporate Update"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy